PT Prodia Widyahusada Tbk (PRDA) Fair Value & Analysis
Healthcare · ID · Market cap 2.1T IDR
Fair value as of: Jul 18, 2026
From 25 valuation models · updated 23 days ago
Share price −2.5% over the past month.
A solid business, screening 110% undervalued on our models.
What matters now
- The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (3,835 IDR). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 2,122 IDR – 7,229 IDR · fair‑value band 3,835 IDR – 6,063 IDR · the 2,370 IDR price screens below the 4,978 IDR fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PT Prodia Widyahusada Tbk (PRDA) currently trades at 2,370 IDR, while our model-based Fair Value estimate is 4,978 IDR, implying the stock looks roughly 110.0% undervalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Prodia Widyahusada Tbk generated revenue of 2.3T IDR at a net margin of 9.4%. Revenue grew 3.8% year over year. It earns a return on equity of 8.8%. The balance sheet holds a net cash position of 568B IDR. Fundamentals as of Jul 18, 2026
Our scenario range runs from 3,835 IDR (bear case) to 6,063 IDR (bull case); at 2,370 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at 110%, PRDA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (6,309 IDR) versus Asset-Based (1,801 IDR). Highest evidence: Growth DCF (80).
Notify me when PRDA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services.
Full company description
PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services. It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Prodia Widyahusada Tbk reported revenue of 2.3T IDR in FY2025 versus 2.7T IDR in FY2021, a compound −3.7%/yr. Reported net income was 207B IDR in FY2025, compounding −24.1%/yr from FY2021.
of which total revenue +7.1 pp · buybacks/dilution −0.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch PRDA: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare PT Prodia Widyahusada Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Prodia Widyahusada Tbk (PRDA) overvalued or undervalued?
What is the fair value of PRDA?
What is the quality score of PRDA?
What is the revenue of PT Prodia Widyahusada Tbk (PRDA)?
What is the net profit margin of PRDA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Prodia Widyahusada Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.